Immunocore Holdings plc - ADR

XNAS:IMCR   4:00:00 PM EDT
33.77
-1.23 (-3.51%)
: $33.68 -0.09 (-0.27%)
Twitter Share  Facebook Share StockTwits Share

Search For a Symbol

Market Cap (Intraday)1.66B
Current PEN/A
Forward PE 241.21
2yr Forward PE N/A
See more stats
Estimates Current Quarter
Revenue$110.21 Million
Adjusted EPS$0.01
See more estimates
10-Day MA$34.22
50-Day MA$30.85
200-Day MA$32.50
See more pivots

Immunocore Holdings plc - ADR Stock, XNAS:IMCR

92 Park Drive, Milton Park, Abingdon, Oxfordshire OX14 4RY
United Kingdom
Phone: +44.1235.438600
Number of Employees: 493
http://immunocore.com

Description

Immunocore Holdings Plc operates as a commercial-stage biotechnology company pioneering the development of a novel class of TCR bispecific immunotherapies called ImmTAX � Immune mobilizing monoclonal TCRs Against X disease. Its lead product KIMMTRAK is a TCR therapeutic for the treatment of patients with unresectable or metastatic uveal melanoma, in the United States, European Union, Canada, Australia and the United Kingdom. Its pipeline products include IMC-F106C, IMC-F115C, IMC-F119C, IMC-F117C, IMC-F113V, IMC-I109V, IMC-SII8AI, among others. The company was founded on January 7, 2021 and is headquartered in Abingdon, the United Kingdom.